2024 ATS Highlights

ATS 2024 was an energizing week for our team. In case we missed you, here are some highlights from our scientific team and academic collaborators:




BEACON Early COPD Analysis Published

A novel early COPD paper was presented at ATS and is featured on the cover of the AJRCCM (Blue Journal). 

What: BEACON is an NHS study of very early COPD development in 30-45 year old smokers. 

Findings: Several quantitative CT (QCT) biomarkers, including VIDA’s proprietary vDPM (ventilation Defect Probability Mapping) biomarker, were predictive of faster FEV1 decline.  Other imaging biomarkers included Pi10, texture analysis (AMFM), and SVV:TPVV (small vessel volume to total pulmonary vessel volume). These imaging biomarkers showed a signal despite normal PFT values.

Conclusions: “Radiological abnormalities on CT are already established in young smokers with normal lung function and are associated with FEV1 loss independently of the impact of symptoms.”

In addition, an editorial by Dr. Pistenmaa and Dr. Washko stated: “These data may also make us reconsider the utility of CT scanning in younger smokers. The ongoing evolution of CT technology is increasingly yielding very low radiation dose images and, on the basis of the BEACON data, we may now anticipate “seeing” something in these scans.”

Select ATS Abstracts 

VIDA's analysis was found throughout the show in dozens of scientific sessions and posters, including those directly produced by VIDA and those developed through academic collaborators. Here are some of the highlights.

Mucus Plug Analysis

Mucus plug analysis was a hot topic at ATS and continues to be one of our most popular biomarker categories. VIDA's mucus analysis was featured in 5 ATS abstracts. Our newest development in this area is comprehensive characterization of mucus plugs, including: distribution/location, mucus burden/composition, and regional functional impact, in addition to mucus plug scoring.



Proximal Mucus Plug Formation Is Associated With Downstream Air Trapping in Severe Asthma 


Reduced Mucus Plugging With Tezepelumab Is Spatially Associated With Reduced Air Trapping in a Broad Population of Patients With Moderate to Severe Asthma Link


Persistence of Mucus Plugging in Severe Asthmatics Treated With Biologics 




Sputum Mucus Rheology, Inflammatory Profile, and CT Mucus Scores in Severe Asthma Link


Imaging biomarkers continue to play a central role in ILD/IPF drug trials. Our mass-based approach to quantifying normal lung tissue garnered attention from ILD therapy providers and researchers. Traditional tissue/texture analysis use volume-based quantification, but we found mass-based measures to be more tightly correlated to clinical tests. Perhaps more importantly, mass-based quantification is more resilient to variability in breath hold effort, allowing for a broader range of scan acquisitions to be used. These new mass-based measures are already included with traditional volume-based measures in our ILD analysis packages. 



Quantification of Normal Tissue Mass From Computed Tomography in Systemic Sclerosis-associated Interstitial Lung Disease (ILD)

Full Poster




Automated Deep Learning-based Airway Count Associates With Lung Function in ILD
Full Poster


Asthma and COPD

We are proud to support SARP and SPIROMICS. Notable abstracts from these cohorts were featured in numerous sessions throughout the show. 



Clinical Characteristics and Longitudinal Outcomes in Heterogeneous Emphysema in SPIROMICS





Quantitative Computed Tomography Characteristics of Persistent Airflow Obstruction in Asthma Patients in the Severe Asthma Research Program (SARP) 




Indoor Air Pollution, Dysanapsis, and Lung Function Decline: Analyses From the SPIROMICS AIR Study



Partner Highlights

Our CTO, Todd Johnson, gave a live demo of OSIC Cloud at the OSIC Symposium. We are proud to support OSIC's mission of making new discoveries in ILD by leveraging the power of rich imaging and clinical data. 


Xenon MRI was another hot topic at ATS, with over 30 abstracts. Polarean’s innovative Xenon MRI solution is now integrated into the VIDA Intelligence Platform for trial sponsors. Polarean offers unparalleled quantitative insights into ventilation, gas exchange, microvascular hemodynamics, and alveolar morphology and diffusion. Discover how these biomarkers can enhance your clinical trials, and how VIDA’s platform enables XeMRI at scale.


4 Block - Simple PNG_no text